Editorial: Liberation

• The sale of Doliprane by Sanofi to the American investment fund CD & R is perceived more as a business move than a medical decision.
• This sale has awakened concerns in France about the availability of Doliprane, especially its version for children.
• Doliprane and its chemical component, paracetamol, are essential in the daily lives of the French, being these the largest consumers in Europe.
• Sanofi's decision to get rid of its Consumer Health division, Opella, is difficult to understand given the demand for paracetamol.

Conclusion: Sanofi's move to sell Doliprane sparks supply concerns. The high demand for paracetamol in France puts into question the reasoning behind this decision.

---